Barry P. Flannelly Sells 959 Shares of Incyte Co. (NASDAQ:INCY) Stock

Incyte Co. (NASDAQ:INCY) EVP Barry P. Flannelly sold 959 shares of the business’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.91, for a total transaction of $76,633.69. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

INCY opened at $80.54 on Friday. The stock has a 50-day moving average price of $82.37. The company has a current ratio of 5.22, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01. Incyte Co. has a twelve month low of $57.00 and a twelve month high of $89.30. The company has a market cap of $17.44 billion, a price-to-earnings ratio of 98.22 and a beta of 1.17.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.29. Incyte had a net margin of 12.66% and a return on equity of 13.28%. The business had revenue of $497.86 million for the quarter, compared to analyst estimates of $488.00 million. During the same quarter in the prior year, the firm earned ($0.01) EPS. The firm’s quarterly revenue was up 30.2% compared to the same quarter last year. As a group, sell-side analysts predict that Incyte Co. will post 1.78 EPS for the current fiscal year.

Several brokerages have issued reports on INCY. BidaskClub lowered shares of Weyco Group from a “sell” rating to a “strong sell” rating in a report on Saturday, July 13th. Stifel Nicolaus began coverage on shares of Seattle Genetics in a report on Wednesday, April 10th. They issued a “hold” rating and a $70.00 price target on the stock. Oppenheimer set a $85.00 price target on shares of Incyte and gave the company a “hold” rating in a report on Sunday, April 7th. Royal Bank of Canada set a €5.70 ($6.63) price target on shares of Banco Santander and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, Cowen reissued a “buy” rating on shares of Incyte in a report on Monday, May 27th. Twelve analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $88.00.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bremer Bank National Association bought a new stake in shares of Incyte during the first quarter valued at approximately $31,000. CX Institutional increased its holdings in shares of Incyte by 1,496.7% during the first quarter. CX Institutional now owns 479 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 449 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its holdings in shares of Incyte by 46.3% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 730 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 231 shares in the last quarter. Machina Capital S.A.S. bought a new stake in shares of Incyte during the fourth quarter valued at approximately $48,000. Finally, Financial Gravity Wealth Inc. bought a new stake in shares of Incyte during the first quarter valued at approximately $51,000. 90.53% of the stock is currently owned by institutional investors and hedge funds.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Article: Understanding each part of a balance sheet

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.